Rain Oncology’s stock dives after tumor treatment fails a PhIII trial

Rain Oncology’s treatment for dedifferentiated liposarcoma failed a Phase III clinical trial, raising questions about what’s next for the Bay Area biotech’s lead candidate. On Monday, Rain Oncology unveiled data from its MANTRA trial investigating milademetan, an oral small molecule inhibitor, in patients with dedifferentiated liposarcoma, a rare type of…

...

Click to view original post